Skip to main content

Table 7 The correlation between CSC marker levels in sera with clinicopathological features and laboratory results in late stage CCA patients

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Variables

Late stage (TNM stage III, IV)

n

CD44

p

CD44v6

p

CD44v8-10

p

EpCAM

p

Sex

 Female

24

0.51 ± 0.16

 

0.80 ± 0.15

 

0.71 ± 0.12

 

0.50 ± 0.17

 

 Male

43

0.52 ± 0.12

0.584

0.78 ± 0.14

0.573

0.70 ± 0.12

0.940

0.47 ± 0.13

0.435

Age (year)

 Less than 61

32

0.51 ± 0.12

 

0.80 ± 0.12

 

0.69 ± 0.10

 

0.46 ± 0.14

 

 61 or greater

35

0.52 ± 0.14

0.769

0.78 ± 0.16

0.651

0.71 ± 0.13

0.505

0.50 ± 0.16

0.289

Tumor site

 Intrahepatic

38

0.50 ± 0.13

 

0.77 ± 0.15

 

0.70 ± 0.11

 

0.46 ± 0.12

 

 Extrahepatic

29

0.54 ± 0.13

0.231

0.82 ± 0.13

0.128

0.71 ± 0.13

0.539

0.50 ± 0.17

0.259

Histology type

 Papillary

29

0.51 ± 0.14

 

0.78 ± 0.15

 

0.70 ± 0.12

 

0.47 ± 0.17

 

 Others

38

0.53 ± 0.13

0.599

0.80 ± 0.14

0.510

0.71 ± 0.12

0.809

0.49 ± 0.13

0.562

Tumor marker

 CA19-9 (U/mL)

  < 37

13

0.47 ± 0.14

 

0.79 ± 0.13

 

0.71 ± 0.13

 

0.44 ± 0.13

 

  ≥ 37

33

0.53 ± 0.13

0.152

0.80 ± 0.16

0.828

0.70 ± 0.11

0.841

0.48 ± 0.13

0.257

 CEA (ng/mL)

  < 2.5

6

0.51 ± 0.20

 

0.71 ± 0.19

 

0.71 ± 0.10

 

0.52 ± 0.09

 

  ≥ 2.5

37

0.51 ± 0.11

0.888

0.80 ± 0.13

0.171

0.69 ± 0.10

0.598

0.44 ± 0.11

0.108

 AFP (IU/mL)

  < 5

33

0.52 ± 0.14

 

0.79 ± 0.16

 

0.70 ± 0.11

 

0.46 ± 0.11

 

  ≥ 5

4

0.45 ± 0.20

0.357

0.77 ± 0.11

0.792

0.61 ± 0.06

0.118

0.38 ± 0.11

0.199

Liver function test

 Direct bilirubin (mg/dL)

  < 1.5

39

0.50 ± 0.14

 

0.77 ± 0.16

 

0.70 ± 0.11

 

0.46 ± 0.13

 

  ≥ 1.5

17

0.56 ± 0.12

0.137

0.85 ± 0.09

0.029

0.71 ± 0.11

0.632

0.51 ± 0.14

0.227

 Total bilirubin (mg/dL)

  < 2.5

35

0.49 ± 0.14

 

0.76 ± 0.16

 

0.68 ± 0.11

 

0.46 ± 0.13

 

  ≥ 2.5

21

0.55 ± 0.12

0.089

0.85 ± 0.11

0.037

0.73 ± 0.11

0.149

0.51 ± 0.13

0.181

 ALT (U/L)

  < 40

28

0.49 ± 0.14

 

0.76 ± 0.16

 

0.70 ± 0.12

 

0.48 ± 0.14

 

  ≥ 40

28

0.54 ± 0.12

0.148

0.83 ± 0.13

0.091

0.70 ± 0.11

0.946

0.47 ± 0.12

0.708

 AST (U/L)

  < 40

25

0.49 ± 0.15

 

0.75 ± 0.18

 

0.68 ± 0.11

 

0.45 ± 0.12

 

  ≥ 40

31

0.54 ± 0.12

0.150

0.83 ± 0.11

0.037

0.72 ± 0.11

0.187

0.49 ± 0.14

0.295

 ALP (U/L)

  < 130

19

0.47 ± 0.13

 

0.74 ± 0.16

 

0.65 ± 0.11

 

0.41 ± 0.11

 

  ≥ 130

37

0.54 ± 0.13

0.056

0.82 ± 0.13

0.049

0.72 ± 0.11

0.024

0.51 ± 0.13

0.006

  1. CD44 cluster of differentiation 44, CD44v CD44 variant, EpCAM epithelial cell adhesion molecules, TNM primary tumor-node-metastasis, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP: alkaline phosphatase
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us